Polypid Ltd

NASDAQ:PYPD  
4.71
+0.13 (+2.84%)
Regulatory, Earnings Announcements

Polypid Announces Recommendation By Data Safety Monitoring Board To Conclude Enrollment Of Phase 3 Shield I Trial Of D-Plex100

Published: 05/23/2022 11:53 GMT
Polypid Ltd (PYPD) - Polypid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 Shield I Trial of D-plex₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis.
Polypid Ltd- Enrollment of 950 Patients, Minimum Number of Patients Targeted for Shield I Study, Expected Within Days.
Polypid Ltd- Top-line Results Expected by End of Q3 2022; Potential NDA and Maa Submissions Targeted for H1 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.62

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.56

More details on our Analysts Page.